Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: An economic evaluation alongside a randomised controlled trial

PharmacoEconomics

Volumn 32, Issue 1, 2014, Pages 87-99

  Wilson, Edward C F ^a,b   Shulgina, Ludmila ^c   Cahn, Anthony P ^d   Chilvers, Edwin R ^e   Parfrey, Helen ^e   Clark, Allan B ^c   Twentyman, Orion P ^f   Wilson, Andrew M ^c,f  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d BEDFORD HOSPITAL NHS TRUST   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC EVALUATION; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HEALTH CARE POLICY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SOCIAL WORK; UNITED KINGDOM;

ANTI-INFECTIVE AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG COSTS; GREAT BRITAIN; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MULTICENTER STUDIES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; UNCERTAINTY;

EID: 84898775824     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0112-z     Document Type: Article

References (34)

1. Shulgina L, Cahn AP, Chilvers ER, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax. 2013;68(2):155-62.
2. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax. 2011;66(6):462-7.
3. Nicholson AG, Colby TV, du Bois RM, et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 2000;162(6):2213-7. (Pubitemid 32051689)
4. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
5. Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2010;(9):CD003134. doi:10.1002/14651858.CD003134.pub2.
6. Varney VA, Parnell HM, Salisbury DT, et al. A double blind randomised placebo controlled pilot study of oral co-trimoxazole in advanced fibrotic lung disease. Pulm Pharmacol Ther. 2008;21(1):178-87.
7. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Pharmacoeconomics. 2013;31(5):361-7. doi:10.1007/s40273-013-0032-y.
8. The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.
9. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095-108. (Pubitemid 127453463)
10. Rubin DB. Multiple imputation for nonresponse in surveys. Hoboken: Wiley; 2004.
11. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810-6. doi:10.1164/rccm.200602-163OC. (Pubitemid 44511663)
12. Office for National Statistics. Statistical bulletin: 2011 census: population estimates for the United Kingdom. 2011. http://www.ons.gov.uk/ons/ rel/census/2011-census/population-and-house hold-estimates-for-the-united- kingdom/stb-2011-census-population-estimates-for-the-united-kingdom.html. Accessed 24 July 2013.
13. Pratt J, Raiffa H, Schlaifer R. Introduction to statistical decision theory. Cambridge: Massachusetts Institute of Technology; 1995.
14. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999;18(3):341-64. doi:10.1016/S0167-6296(98)00039-3. (Pubitemid 29242816)
15. Byford S, Raftery J. Perspectives in economic evaluation. BMJ. 1998;316(7143):1529-30.
16. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999;319(7211):670-4. (Pubitemid 29423954)
17. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2005;14(5):487-96. doi:10.1002/hec.944. (Pubitemid 40723857)
18. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. Accessed http://www.nice.org.uk/media/B52/A7/ TAMethodsGuideUpdatedJune2008.pdf.
19. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431-40. doi:10.1164/rccm.201006-0894CI.
20. Kim DS, Park JH, Park BK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006;27(1):143-50. doi:10.1183/09031936.06.00114004. (Pubitemid 43092678)
21. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37(2):356-63. doi:10.1183/09031936.00159709.
22. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(4):459-66. doi:10.1164/rccm.201011-1790OC.
23. Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968-77. doi:10.1056/NEJMoa1113354.
24. Dempsey OJ, Welham S, Hirani N. P84 BTS National Interstitial Lung Diseases (ILD) Survey 2010-2011. Thorax. 2011;66(Suppl 4):A102. doi:10.1136/thoraxjnl-2011-201054c.84.
25. Hagaman JT, Kinder BW, Eckman MH. Thiopurine S-methyl-transferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung. 2010;188(2):125-32. doi:10.1007/s00408-009- 9217-8.
26. Molin LJ, Steinberg JB, Lanza LA.VATS increases costs in patients undergoing lung biopsy for interstitial lung disease. Ann Thorac Surg. 1994;58(6):1595-8. doi:10.1016/0003-4975(94)91638-1. (Pubitemid 24378962)
27. Weycker D, Oster G, Edelsberg J, et al. Economic costs of idiopathic pulmonary fibrosis: annual meeting of the American College of Chest Physicians. Chest. 2002:150s.
28. Ayres JG, Boyd R, Cowie H, et al. Costs of occupational asthma in the UK. Thorax. 2011;66(2):128-33. doi:10.1136/thx.2010.136762.
29. NHS Health and Social Care Information Centre. Prescription cost analysis. 2011. http://www.ic.nhs.uk/pubs/prescostanalysis2011. Accessed 22 March 2013.
30. Office for National Statistics. United Kingdom National Accounts-The Blue Book 2012 Edition; 2012. http://www.ons.gov.uk/ons/rel/naa1-rd/united-kingdom- national-accounts/the-bluebook-2012-edition/index.html
31. Department of Health: National Schedule of Reference Costs 2011-12 for NHS Trusts and NHS Foundation Trusts. Appendix NSRC01. https://www.gov.uk/ government/uploads/system/uploads/attachment-data/file/127114/Nationalschedules. zip.zip
32. Curtis L. Unit costs of health and social care 2012. Canterbury: University of Kent at Canterbury; 2013.
33. Office for National Statistics. Annual survey of hours and earnings, 2012 provisional results. 2012. http://www.ons.gov.uk/ons/dcp171778-286243.pdf
34. British National Formulary 62. 62 ed. London: British Medical Journal Group & Royal Pharmaceutical Society of Great Britain; 2011. http://www.bnf.org